Trial · NCT05705193
Brain-Training Treatment for Long COVID in Older Adults
NCT05705193, Not applicable, Completed, UConn Health
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Brain-Training Treatment for Long COVID in Older Adults. Trials, record NCT05705193. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05705193
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Brain-Training Treatment for Long COVID in Older Adults
- NCT number
- NCT05705193
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 39 participants, actual
- Lead sponsor
- UConn Health
- Conditions
- Post-Acute COVID-19 Syndrome
- Interventions
- NeuroFlex (computerized gamified tasks)
- First posted
- 2023-01-30
- Last updated
- 2026-08-14
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Acceptability/Adherence Scale (TAAS) | The investigators will evaluate TAAS Total Score at the outset of treatment (expected/anticipated acceptability and adherence) and at post-treatment (6 weeks) | Treatment acceptability and adherence as measured by the TAAS Total Score; higher scores on this self-report measure indicate greater treatment acceptability and adherence |
| Primary | Credibility/Expectancy Questionnaire (CEQ) | The investigators will evaluate CEQ Total Score at the outset of treatment (to assess initial perceptions of treatment credibility) and at post-treatment (6 weeks) | Treatment credibility and expectancy as measured by the CEQ Total Score; higher scores on this self-report measure indicate greater treatment credibility and expectancy |
| Primary | System Usability Scale (SUS) | The investigators will evaluate SUS Total Score at the outset of treatment (to assess initial perceptions of treatment usability) and at post-treatment (6 weeks) | Usability of the intervention as measured by the SUS Total Score; higher scores on this self-report measure indicate greater perceived usability |
| Primary | Feasibility (proportion of subjects who agree to participate in the offered treatment, complete assigned exercises, and complete the entire treatment regimen) | Our feasibility criteria will be assessed by calculating percentages at the conclusion of the study | Feasibility will be assessed according to the following criteria: 1) at least 80% of eligible subjects offered the treatment agree to participate; 2) subjects will complete at least 80% of assigned treatment exercises; 3) at least 80% of participants who start the treatment will finish it. |
| Secondary | Trail Making Test Part B | The investigators will evaluate change in time (seconds) to complete the Trail Making Test Part B at post-treatment (6 weeks) relative to pre-treatment (baseline) | Set-shifting abilities as measured by time to complete the Trail Making Test Part B in seconds; lower scores indicate better set-shifting performance |
| Secondary | Montgomery-Asberg Depression Scale (MADRS) | The investigators will evaluate change in Total MADRS Score at post-treatment (6 weeks) relative to pre-treatment (baseline) | Depressive symptoms as measured by the Total MADRS Score; lower scores indicate less depressive symptoms |
| Secondary | World Health Organization Disability Assessment Schedule (WHODAS) | The investigators will evaluate change in Total WHODAS Score at post-treatment (6 weeks) relative to pre-treatment (baseline) | Functional disability as measured by the Total WHODAS Score; lower scores indicate less functional disability |
| Secondary | Everyday Cognition (ECog) | The investigators will evaluate change in Total ECog Score at post-treatment (6 weeks) relative to pre-treatment (baseline) | Subjective cognitive concerns as measured by the Total ECog Score; lower scores indicate less subjective cognitive concern |
| Secondary | Verbal Fluency | The investigators will evaluate change in total number of words produced at post-treatment (6 weeks) relative to pre-treatment (baseline) | Verbal generativity as measured by the total number of words produced according to pre-specified rules; higher scores indicate better verbal generativity performance |
| Secondary | Stroop Color and Word Test | The investigators will evaluate change in total correct responses at post-treatment (6 weeks) relative to pre-treatment (baseline) | Inhibitory control as measured by total correct responses on the inhibition condition of the Stroop Test; higher scores indicate better inhibitory control performance |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30AG067988 | Claude D. Pepper Older Americans Independence Center | KUCHEL, GEORGE A; Fortinsky, Richard H | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT | NATIONAL INSTITUTE ON AGING | 2021 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Delayed Recall Module | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05705193
GET https://conductscience.org/api/trials/v1/NCT05705193/registered